Debates & Didactics in Hematology & Oncology Conference Agenda
THURSDAY, JULY 21
Time
Topic
Speaker
Moderator: Joshua Simmons, MD
Genitourinary Cancers
7:40 – 8:05 AM
DEBATE
Neoadjuvant vs Adjuvant treatment in Localized Upper Tract Urothelial Cancer
8:05 – 8:25 AM
What is New in Prostate Cancer Treatment
8:25 – 8:45 AM
Sequencing of Therapies and Novel Agents in Metastatic Renal Cell Cancer
8:45 – 9:05 AM
Management of Rare Genitourinary Cancers (adenoid cystic carcinoma, penile)
9:05 – 9:25 AM
Treatment Updates in Metastatic Urothelial Cancer
9:25 – 9:45 AM
Patient-based Panel Discussion with ASCO Highlights and Q&A
All speakers
9:45 – 10:10 AM
Break
Head and Neck
10:10 – 10:30 AM
Updates on EGFR-targeted Therapies and Immunotherapies in SCCHN
10:30 – 10:55 AM
DEBATE
Proton Therapy is Superior to IMRT in the Definitive Radiation Therapy Setting: Yes vs No
Proton Therapy is Superior to IMRT in the Definitive Radiation Therapy Setting: Yes vs No
10:55 – 11:15 AM
Patient-based Panel Discussion with ASCO Highlights and Q&A
All speakers
11:15 – 12:00 AM
Lunch
Moderator: Bradley Sumrall, MD
Brain Cancer
Lymphomas Part 1
12:20 – 12:45 PM
DEBATE
R-CHOP vs Pola-R-CHP for Untreated DLBCL
R-CHOP vs Pola-R-CHP for Untreated DLBCL
12:45 – 1:10 PM
DEBATE
CAR T vs Auto-transplant for Relapsed DLBCL
CAR T vs Auto-transplant for Relapsed DLBCL
1:10 – 1:30 PM
Current Management of Relapsed/Refractory MCL
1:50 – 2:10 PM
Patient-based Panel Discussion with ASH Highlights and Q&A
All speakers
FRIDAY, JULY 22
Time
Topic
Speaker
Moderator: Eric Turner, MD
Melanoma
7:35 – 7:55 AM
Improving Survival in Metastatic Uveal Melanoma
7:55 – 8:15 AM
Improving Outcomes for PD-1 Resistant Melanoma: What’s On the Horizon?
8:15 – 8:40 AM
DEBATE
Stage II Melanoma: Is Adjuvant Treatment Appropriate? Yes vs No
Stage II Melanoma: Is Adjuvant Treatment Appropriate? Yes vs No
8:40 – 9:05 AM
DEBATE
Stage II Melanoma: Is Adjuvant Treatment Appropriate? Yes vs No
Stage II Melanoma: Is Adjuvant Treatment Appropriate? Yes vs No
8:40 – 9:00 AM
Patient-based Panel Discussion with ASCO Highlights and Q&A
All speakers
9:00 – 9:25 AM
Break
Leukemia
9:45 – 10:10 AM
DEBATE
Should We Transplant Relapsed AML/MDS Not in Remission? Yes vs No
Should We Transplant Relapsed AML/MDS Not in Remission? Yes vs No
10:10 – 10:35 AM
DEBATE
Should CAR T Therapy Replace alloHCT in B-cell ALL?
Should CAR T Therapy Replace alloHCT in B-cell ALL?
10:35 – 11:05 AM
Novel Therapies in Myeloproliferative Neoplasms: Ruxolitinib Combinations and Beyond
11:05 – 11:25 AM
Patient-based Panel Discussion with ASH Highlights and Q&A
All speakers
11:15 – 11:35 AM
Patient-based Panel Discussion with ASH Highlights and Q&A
All speakers
11:25 – 12:10 PM
Lunch
Moderator: Richard LoCicero, MD
Lecture of the Day
12:10 – 12:35 PM
Success of Precision Medicine Q&A moderated by Medical Oncology fellow
Gastrointestinal Cancers
12:35 – 12:55 PM
Updates on Total Neoadjuvant Therapy and Watch & Wait in Rectal Cancer Management
12:55 – 1:15 PM
Sequencing Treatment Options in Hepatocellular Carcinoma
1:15 – 1:40 PM
DEBATE
Circulating Tumor DNA to Guide Adjuvant Therapy in Colorectal Cancer is Ready for Prime Time: Yes vs No
Circulating Tumor DNA to Guide Adjuvant Therapy in Colorectal Cancer is Ready for Prime Time: Yes vs No
1:40 – 2:00 PM
Management of Relapsed Pancreatic Cancer
2:00 – 2:20 PM
Patient-based Panel Discussion with ASCO Highlights and Q&A
All speakers
SATURDAY, JULY 23
Time
Topic
Speaker
Moderator: Missy Dillmon, MD
Thoracic Cancers
8:05 – 8:25 AM
Updates in Targeted Therapy for Advanced NSCLC
8:25 – 8:50 AM
DEBATE
NGS at the Time of Diagnosis for Advanced NSCLC (Tissue AND Plasma vs Tissue OR Plasma)
NGS at the Time of Diagnosis for Advanced NSCLC (Tissue AND Plasma vs Tissue OR Plasma)
8:50 – 9:10 AM
Updates in Immunotherapy for Metastatic NSCLC
9:10 – 9:30 AM
Perioperative Immunotherapy in NSCLC
9:30 – 9:50 AM
Patient-based Panel Discussion with ASCO Highlights and Q&A
All speakers
9:50 – 10:10 AM
Break
Gynecologic Cancers
10:10 – 10:30 AM
Emerging Approaches for Recurrent Endometrial Cancer and Advanced Ovarian Cancer
Lymphomas Part 2
10:30 – 10:50 AM
Developments in T-cell Lymphoma
10:50 – 11:10 AM
Best Management of Elderly Patients with HL (and/or NHL)
Lecture of the Day
11:10 – 11:35 AM
Multi-cancer Early Detection Technology
Q&A moderated by Medical Oncology fellow
11:35 – 12:20 PM
Lunch
Moderator: Ethan Tolbert, MD
Lecture of the Day
11:40 – 12:05 PM
Multi-cancer Early Detection Technology
Q&A moderated by Medical Oncology fellow
Q&A moderated by Medical Oncology fellow
Myeloma
12:20 – 12:40 PM
Evolution of Modern Induction Regimens in Myeloma: What Does the Future Hold?
12:40 – 1:05 PM
DEBATE
IMID or PI-based Salvage for First Relapse Myeloma
IMID or PI-based Salvage for First Relapse Myeloma
1:05 – 1:25 PM
Choice of Treatment for Relapsed t(11;14) Myeloma: BCL2 Inhibitors or Immunotherapy?
1:25 – 1:45 PM
Cellular Therapies vs Bi-specifics for Multiple Myeloma
1:45 – 2:10 PM
DEBATE
Does Precision Medicine have a Role in MM in the Era of Immune Therapies? Yes vs No
Does Precision Medicine have a Role in MM in the Era of Immune Therapies? Yes vs No
2:10 – 2:30 PM
Patient-based Panel Discussion with ASH Highlights and Q&A
All speakers
SUNDAY, JULY 24
Time
Topic
Speaker
Moderator: Mark Taylor, MD
Breast Cancer
8:05 – 8:25 AM
Neoadjuvant Therapy and LocregionalControl: A Surgeon’s Perspective
8:25 – 8:45 AM
Ultra-Short Radiation for Early-Stage Breast Cancer: Is 5 treatments the new standard?
8:45 – 9:05 AM
Operable HR+/HER2- Breast Cancer: When to Do Less and When To Do More
9:05 – 9:25 AM
Advances in Metastatic Triple Negative Breast Cancer: Immunotherapy, Antibody Drug Conjugates, and Beyond
9:25 – 9:50 AM
DEBATE
Stage I Triple Negative Breast Cancer: Neoadjuvant Therapy? Yes or No
Stage I Triple Negative Breast Cancer: Neoadjuvant Therapy? Yes or No
9:50 – 10:10 AM
Patient-based Panel Discussion with ASCO Highlights and Q&A
All speakers
